Yuce Biological Technology
1
61M
1
0.17
- Areas of investment
Summary
In 2015 was created Yuce Biological Technology, which is appeared as Corporate Investor. The fund was located in Asia if to be more exact in China. The leading representative office of defined Corporate Investor is situated in the Shenzhen.
Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. The high activity for fund was in 2019.
Among the most successful fund investment fields, there are Non Profit, Association. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline MabPlex International
The usual cause for the fund is to invest in rounds with 8 partakers. The meaningful sponsors for the fund in investment in the same round are Thousand Oaks Biopharmaceuticals, Shenzhen Capital Group, SDIC Venture Capital.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.17
- Investments by industry
- Association (1)
- Non Profit (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| MabPlex International | 17 Jan 2019 | Non Profit, Association | Early Stage Venture | 61M | United States, California, Fremont |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.